The affordability of newly approved anticancer agents is a challenge to many national health services and reimbursement systems. Therefore, we have developed an approach based upon the adoption of a novel model of price setting and herein provide examples of how it might be implemented. This model is intended to alter the balance between social and economic entrepreneurship.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund
Gene Therapy Open Access 24 April 2024
-
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer
Targeted Oncology Open Access 21 April 2023
-
Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports
Cost Effectiveness and Resource Allocation Open Access 31 August 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
International Agency for Research on Cancer & World Health Organization. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. IARC http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (2017).
Luengo-Fernandez, R. et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 14, 1165–1174 (2013).
Davis, C. et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–2013. BMJ 359, j4530 (2017).
Chandra, A., Shafrin, J. & Dhawan, R. Utility of cancer value frameworks for patients, payers, and physicians. JAMA. 315, 2069–2070 (2016).
OncLive. Enzalutamide pricing debate goes to Washington. OncLive http://www.onclive.com/publications/oncology-business-news/2016/may-2016/enzalutamide-pricing-debate-goes-to-washington (2016).
Orphan Druganaut Blog. What is the price of orphan drug ruxolitinib? Orphan Druganaut Blog https://orphandruganaut.wordpress.com/2012/09/18/what-is-the-price-of-orphan-drug-ruxolitinib (2012).
DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016).
Prasad, V. & Mailankody, S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern. Med. 177, 1569–1575 (2017).
Marseille, E. et al. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull. World Health Organ. 93, 118–124 (2015).
American Society of Clinical Oncology. American Society of Clinical Oncology position statement on addressing the affordability of cancer drugs. ASCO https://www.asco.org/sites/new-www.asco.org/files/content-files/blog-release/documents/2017-ASCO-Position-Statement-Affordability-Cancer-Drugs.pdf (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.U.-d.G. has received unrestricted grants for research within the Erasmus University from Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Genzyme, Gilead, Janssen-Cilag, Merck, Roche and Sanofi. B.L. has received personal fees from Agros Pharmaceuticals, Astellas, ASTEX, Celgene, Clear Creek Bio, F. Hoffman-La Roche, Novartis and Seattle Genetics.
Supplementary information
41571_2018_27_MOESM2_ESM.pdf
Supplementary file 2 Explanation of algorithm of cost price calculation for new (cancer) drugs with an application to enzalutamide and ruxolitinib
Rights and permissions
About this article
Cite this article
Uyl-de Groot, C.A., Löwenberg, B. Sustainability and affordability of cancer drugs: a novel pricing model. Nat Rev Clin Oncol 15, 405–406 (2018). https://doi.org/10.1038/s41571-018-0027-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0027-x
This article is cited by
-
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund
Gene Therapy (2024)
-
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer
Targeted Oncology (2023)
-
Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports
Cost Effectiveness and Resource Allocation (2022)
-
Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies
BMC Health Services Research (2021)
-
The impact of early phase price agreements on prices of orphan drugs
BMC Health Services Research (2021)